Common use of Definitions and Miscellaneous Provisions Clause in Contracts

Definitions and Miscellaneous Provisions. (i) GSK shall continue to make each annual listing and the most recent quarterly listing of Payments available on its website during the term of the CIA. GSK shall retain and make available to OIG, upon request, all supporting documentation, correspondence, and records related to all applicable Payments and to the annual and/or quarterly listings of Payments. Nothing in this Section III.O affects the responsibility of GSK to comply with (or liability for noncompliance with) all applicable Federal health care program requirements and state laws as they relate to all applicable Payments made to physicians or Related Entity. (ii) For purposes of Section III.O.1, “Payments” is defined to include all “payments or other transfers of value” as that term is defined in §1128G(e)(10) under Section 6002 of the Affordable Care Act and any regulations promulgated thereunder. The term Payments includes, by way of example, the types of payments or transfers of value enumerated in §1128G(a)(1)(A)(vi) of the Affordable Care Act. The term includes all payments or transfers of value made to Related Entities on behalf of, at the request of, for the benefit or use of, or under the name of a physician for whom GSK would otherwise report a Payment if made directly to the physician. The term Payments also includes any payments or transfers of value made, directly by GSK or by a vendor retained by GSK to a physician or Related Entity in connection with, or under the auspices of, a co-promotion arrangement. GlaxoSmithKline LLC Corporate Integrity Agreement

Definitions and Miscellaneous Provisions. (i) GSK Endo shall continue to make each annual listing and the most recent quarterly listing of Payments available on its website during the term of the CIA. GSK Endo shall retain and make available to OIG, upon request, all supporting documentation, correspondence, and records related to all applicable Payments and to the annual and/or quarterly listings of Payments. Nothing in this Section III.O III.M affects the responsibility of GSK Endo to comply with (or liability for noncompliance with) all applicable Federal health care program requirements and state laws as they relate to all applicable Payments made to physicians or Related Entity. (ii) For purposes of Section III.O.1III.M.1, “Payments” is defined to include all “payments or other transfers of value” as that term is defined in §1128G(e)(10) under Section 6002 of the Patient Protection and Affordable Care Act (Public Law 111-148) (Affordable Care Act) and any regulations promulgated thereunder. The term Payments Endo Pharmaceuticals Inc. Corporate Integrity Agreement includes, by way of example, the types of payments or transfers of value enumerated in §1128G(a)(1)(A)(vi) of the Affordable Care Act. The term includes all payments or transfers of value made to Related Entities on behalf of, at the request of, for the benefit or use of, or under the name of a physician for whom GSK Endo or EPI would otherwise report a Payment if made directly to the physician. The term Payments also includes any payments or transfers of value made, directly by GSK Endo, EPI, or by a vendor retained by GSK Endo or EPI to a physician or Related Entity in connection with, or under the auspices of, a co-promotion arrangement. GlaxoSmithKline LLC Corporate Integrity Agreement. (iii) For purposes of its annual and quarterly website postings as described above, and only with regard to payments made pursuant to product research or development agreements and clinical investigations as set forth in § 1128G(c)(E) of the Affordable Care Act, Endo may delay the inclusion of such payments on its website listings consistent with § 1128G(c)(E) of the Act and any subsequent regulations promulgated thereunder. (iv) The term “Payments” does not include transfers of value or other items that are not included in or are excluded from the definition of “payment” as set forth in § 1128G(e)(10) under Section 6002 of the Affordable Care Act and any regulations promulgated thereunder. (v) For purposes of this Section III.M, the term “Related Entity” is defined to be any entity by or in which any physician receiving Payments is employed, has tenure, or has an ownership interest.

Definitions and Miscellaneous Provisions. (i) GSK Amgen shall continue to make each annual listing and the most recent quarterly listing of Payments available on its website during the term of the CIA. GSK Amgen shall retain and make available to OIG, upon request, all supporting documentation, correspondence, and records related to all applicable Payments and to the annual and/or quarterly listings of Payments. Nothing in this Section III.O III.M affects the responsibility of GSK Amgen to comply with (or liability for noncompliance with) all applicable Federal health care program requirements and state laws as they relate to all applicable Payments made to physicians or Related Entity. (ii) For purposes of Section III.O.1III.M.1, “Payments” is defined to include all “payments or other transfers of value” as that term is defined in §1128G(e)(10) under Section 6002 of the Patient Protection and Affordable Care Act (Public Law 111- 148) (Affordable Care Act) and any regulations promulgated thereunder. The term Payments includes, by way of example, the types of payments or transfers of value enumerated in §1128G(a)(1)(A)(vi) of the Affordable Care Act. The term includes all payments or transfers of value made to Related Entities on behalf of, at the request of, for the benefit or use of, or under the name of a physician for whom GSK Amgen would otherwise report a Payment if made directly to the physician. The term Payments also includes any payments or transfers of value made, directly by GSK Amgen or by a vendor retained by GSK Amgen to a physician or Related Entity in connection with, or under the auspices of, a co-co- promotion arrangement. (iii) For purposes of its annual and quarterly website postings as described above, and only with regard to payments made pursuant to product research or development agreements and clinical investigations as set forth in § 1128G(c)(E) of the Affordable Care Act, Amgen may delay the inclusion of such payments on its website listings consistent with § 1128G(c)(E) of the Act and any subsequent regulations promulgated thereunder. GlaxoSmithKline LLC Corporate Integrity AgreementAgreement Amgen Inc. (iv) The term “Payments” does not include transfers of value or other items that are not included in or are excluded from the definition of “payment” as set forth in § 1128G(e)(10) under Section 6002 of the Affordable Care Act and any regulations promulgated thereunder. (v) For purposes of this Section III.M, the term “Related Entity” is defined to be any entity by or in which any physician receiving Payments is employed, has tenure, or has an ownership interest.